RANDOMIZED PHASE II TRIAL OF ADJUVANT WT-1 ANALOG PEPTIDE VACCINE IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA AFTER COMPLETION OF MULTIMODALITY T
$1,487,972FY2010Department of DefenseDOD
Sloan-Kettering Institute For Cancer Research
Sloan-Kettering Institute For Cancer Research